Cargando…

Is overreliance on short-acting β(2)-agonists associated with health risks in the older asthma population?

Recent Global Initiative for Asthma (GINA) recommendations reduce the role of short-acting β(2)-agonist (SABA) premised on the associated exacerbation risk. The widely accepted SABA risk profile is based on limited data described 30 years ago. This GINA paradigm shift demands an examination of SABA...

Descripción completa

Detalles Bibliográficos
Autores principales:	To, Teresa, Zhu, Jingqin, Terebessy, Emilie, Zhang, Kimball, Gershon, Andrea S., Licskai, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958218/ https://www.ncbi.nlm.nih.gov/pubmed/35350274 http://dx.doi.org/10.1183/23120541.00032-2022

Ejemplares similares

Healthcare utilization in Canadian children and young adults with asthma during the COVID-19 pandemic
por: To, Teresa, et al.
Publicado: (2023)

Effect of smoke-free legislation on respiratory health services use in children with asthma: a population-based open cohort study in Ontario, Canada
por: To, Teresa, et al.
Publicado: (2021)

Correlation of ambient temperature and COVID-19 incidence in Canada
por: To, Teresa, et al.
Publicado: (2021)

Behavioral and neuroimaging evidence for overreliance on habit learning in alcohol-dependent patients
por: Sjoerds, Z, et al.
Publicado: (2013)

mSphere of Influence: Going Native, or the Risk of Overreliance on Recombinant Antigens
por: Lopez-Perez, Mary
Publicado: (2020)

UV, ozone, and COVID-19 transmission in Ontario, Canada using generalised linear models
por: To, Teresa, et al.
Publicado: (2021)

Does an mHealth system reduce health service use for asthma?
por: To, Teresa, et al.
Publicado: (2020)

SABINA: An Overview of Short-Acting β(2)-Agonist Use in Asthma in European Countries
por: Janson, Christer, et al.
Publicado: (2020)

The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

It is time to end our love affair with short-acting β(2)-agonists in asthma
por: Crooks, Michael G., et al.
Publicado: (2022)

Short-acting β(2)-agonists and exacerbations in children with asthma in England: SABINA Junior
por: Morgan, Ann, et al.
Publicado: (2023)

Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β(2)-Agonist–Only Treatment
por: Baraldi, Eugenio, et al.
Publicado: (2022)

Sex differences in health services and medication use among older adults with asthma
por: To, Teresa, et al.
Publicado: (2019)

It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes
por: Nannini, Luis J.
Publicado: (2023)

Healthcare costs associated with short-acting β(2)-agonists in asthma: observational UK SABINA study
por: Attar-Zadeh, Darush, et al.
Publicado: (2023)

The magnitude of neurocognitive impairment is overestimated in depression: the role of motivation, debilitating momentary influences, and the overreliance on mean differences
por: Moritz, Steffen, et al.
Publicado: (2023)

Overreliance on Radiological Findings Leading to Misdiagnosed Giant Retroperitoneal Ganglioneuroma: A Case Report and Literature Review
por: Shah, Dharmendra, et al.
Publicado: (2023)

The Burden of Short-Acting β(2)-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program
por: Di Marco, Fabiano, et al.
Publicado: (2021)

Short-acting β(2)-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III
por: Yorgancıoğlu, Arzu, et al.
Publicado: (2022)

Short-acting β(2)-agonist prescription patterns for asthma management in the SABINA III primary care cohort
por: Price, David, et al.
Publicado: (2022)

Short‐acting β(2)‐agonist use and asthma exacerbations in Swedish children: A SABINA Junior study
por: Melén, Erik, et al.
Publicado: (2022)

Reply to Baraldi and Piacentini: Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β(2)-Agonist–Only Treatment
por: Duijts, Liesbeth, et al.
Publicado: (2022)

Does early life exposure to exogenous sources of reactive oxygen species (ROS) increase the risk of respiratory and allergic diseases in children? A longitudinal cohort study
por: To, Teresa, et al.
Publicado: (2022)

Short-Acting Beta2-Agonist Use in Asthma in Korea: A 10-Year Population-Based Study
por: Lee, Hyun, et al.
Publicado: (2021)

Over-prescription of short-acting β(2)-agonists and asthma management in the Gulf region: a multicountry observational study
por: Alzaabi, Ashraf, et al.
Publicado: (2022)

Over-prescription of short-acting β(2)-agonists for asthma in South Africa: Results from the SABINA III study
por: Smith, C, et al.
Publicado: (2022)

Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β(2)-agonists: A systematic review
por: Loh, Zhe Chi, et al.
Publicado: (2023)

Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study
por: Molina, Jesús, et al.
Publicado: (2023)

The Air Quality Health Index and Asthma Morbidity: A Population-Based Study
por: To, Teresa, et al.
Publicado: (2012)

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
por: Worth, Heinrich, et al.
Publicado: (2021)

ICS-formoterol reliever versus ICS and short-acting β(2)-agonist reliever in asthma: a systematic review and meta-analysis
por: Hatter, Lee, et al.
Publicado: (2021)

Overprescription of short‐acting β(2)‐agonists among patients with asthma in Saudi Arabia: Results from the SABINA III cohort study
por: Al‐Jahdali, Hamdan, et al.
Publicado: (2022)

A Cross-Sectional Study on Prescription Patterns of Short-Acting β(2)-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort
por: Pedrozo-Pupo, John Carlos, et al.
Publicado: (2022)

Factors Associated with Failure of Intermittent Nebulization with Short-Acting Beta-Agonists in Children with Severe Asthma Exacerbation
por: Kulalert, Prapasri, et al.
Publicado: (2020)

Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
por: Kaye, Leanne, et al.
Publicado: (2022)

Prediction of short-acting beta-agonist usage in patients with asthma using temporal-convolutional neural networks
por: Hirons, Nicholas, et al.
Publicado: (2023)

Health risk of air pollution on people living with major chronic diseases: a Canadian population-based study
por: To, Teresa, et al.
Publicado: (2015)

Overreliance on China and dynamic balancing in the shift of global value chains in response to global pandemic COVID-19: an Australian and New Zealand perspective
por: Gao, Hongzhi, et al.
Publicado: (2020)

Short-acting β(2)-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study
por: Bateman, Eric D., et al.
Publicado: (2022)

Paradoxical Bronchoconstriction with Short-Acting Beta Agonist
por: Magee, Jared S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ui66nur3sss71kppfm4d4iejd0